Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery

Keyphrases

• Coronary Artery Bypass Graft Surgery 100%
• Coronary Artery Bypass Grafting 100%
• Cardiovascular Events 100%
• Alirocumab 100%
• Acute Coronary Syndrome 58%
• Major Adverse Cardiovascular Events 33%
• Prior Coronary Artery Bypass Grafting 25%
• Cardiovascular Mortality 16%
• Confidence Interval 16%
• Atherogenic Lipoproteins 16%
• Hazard Ratio 8%
• All-cause Mortality 8%
• High Risk 8%
• Placebo 8%
• Hospitalization 8%
• Ischemic Stroke 8%
• Clinical Benefit 8%
• Composite Endpoint 8%
• Statins 8%
• Cardiovascular Outcomes 8%
• Nonfatal Myocardial Infarction 8%
• Trial Results 8%
• Odyssey 8%
• Absolute Risk Reduction 8%
• Lipoprotein Levels 8%
• Absolute Reductions 8%
• Recurrent Cardiovascular Events 8%
• Stable Angina 8%
• Coronary Heart Disease Mortality 8%
• High-intensity Statin Therapy 8%
• Intensive Statin Therapy 8%
• Post-acute Coronary Syndrome 8%

Pharmacology, Toxicology and Pharmaceutical Science

• Acute Coronary Syndrome 100%
• Alirocumab 100%
• Patient History of Coronary Artery Bypass Graft 50%
• Cardiovascular Disease 50%
• Statin (Protein) 25%
• Lipoprotein 25%
• Heart Infarction 12%
• Placebo 12%
• Brain Ischemia 12%
• Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor 12%
• Cause of Death 12%
• Ischemic Heart Disease 12%
• Unstable Angina Pectoris 12%